Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Innovacell on a Collaboration and License Agreement with Norgine

January 9, 2014

LONDON, 9 January, 2014 — Covington & Burling advised Innovacell Biotechnologie AG on a collaboration and exclusive licensing agreement with Norgine BV. Under the terms of the agreement Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence. The agreement territory includes Europe (excluding Russia and Turkey), the Southern African Development Community and Middle East & North Africa regions.

Innovacell Biotechnologie AG is an innovative biotechnology company based in Austria that develops personalized cell therapies for treatment of ‎incontinence.‎ Norgine is an independent European specialty pharmaceutical company with a focus on the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and critical and supportive care.

The Covington team was led by partner Daniel Pavin and included partner Grant Castle (regulatory), special counsel Michael Clancy (EU Competition) and associate Lina Gugucheva.

Share this article: